Synapto

Synapto is an early stage biotech company revolutionizing Alzheimer's diagnosis through portable EEG and Machine Learning. Currently, Alzheimer's is the sixth leading cause of death in the United States, affecting nearly 44 million people worldwide. According to the 2016 World Alzheimer Report, 20 to 50% of patients were not properly diagnosed in middle to high income countries, and due to lack of medical infrastructure and access to care, less than 10% were diagnosed in low-income countries. Their innovative device moves away from costly neuroimaging diagnostic techniques and qualitative methods of diagnosis to a more robust, affordable, and objective measure of analysis, a portable Electroencephalogram (EEG). They are currently seeking FDA approval (under the 510(k) Class 2 Medical Device Pathway) to continue their work. Synapto has already won 1st place in National Institute of Health’s DEBUT competition and has been featured in more than 27 news outlets including Forbes, Science Magazine, and Washingtonian.